Biomarin Pharmaceutical Inc. · NASDAQ:BMRN
Biomarin Pharmaceutical — Q1 2026 Earnings Presentation
21 slides from Biomarin Pharmaceutical's earnings presentation, May 4, 2026
Slide 1: First Quarter 2026 Earnings
First Quarter 2026 Earnings May 4, 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and the associated conference call and webcast contain forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including, without limitation, statements about: future financial performance, including the expecta
Slide 3: Q1'26 Earnings Agenda
Q1'26 Earnings Agenda: 1 Key Business Updates 2 Financial Results 3 Commercial Update 4 Research & Development Update 5 Q&A Alexander Hardy Brian Mueller Cristin Hubbard Greg Friberg Chief Executive Officer Chief Financial Officer Chief Commercial Officer Chief R&D Officer
Slide 4: Q1'26 Key Business Updates
Q1'26 Key Business Updates Alexander Hardy Chief Executive Officer 4
Slide 5: Poised for Accelerated Growth in 2026
GROWTH Poised for Accelerated Growth in 2026 Updated FY’26 Total Revenues Guidance Anticipated Key Highlights in 2026 $ in millions Expand Reach with New Assets +20%1 Y/Y BMN 401 $3,825 to $3,925 ENPP1 deficiency Fabry Disease Pompe Disease $3,221 Advance Lifecycle Innovation BMN 333 hypochondroplas
Slide 6: Q1'26 Financial Results
Q1'26 Financial Results Brian Mueller Chief Financial Officer 6
Slide 7: Solid Q1'26 Revenue; 2H'26 Outlook Ramps Significantly
Solid Q1’26 Revenue; 2H’26 Outlook Ramps Significantly Total Revenues Enzyme Therapies $ in millions Y/Y Change • Q1’26 revenue increased 6%, Y/Y, led by VIMIZIM, Q1 NAGLAZYME, and BRINEURA $745 $766 +3% • PALYNZIQ revenue reflected elevated U.S. stocking in Q4’25; New patient starts grew in Q1 • An
Slide 8: Q1'26 Results Reflect Impact of Cost of Sales and Pre-Close Charges
GROWTH Q1'26 Results Reflect Impact of Cost of Sales and Pre-Close Charges Cost of Sales Q1 2026 Results • NAGLAZYME charge of ~$31M expected to be offset In millions, except percentages and per Y/Y in FY’26 Non-GAAP Diluted EPS guidance Q1’26 share amounts Change Non-GAAP R&D and SG&A GAAP Cost of
Slide 9: Updated Full-year 2026 Guidance
Updated Full-year 2026 Guidance (Including Post-close Contributions from Amicus Acquisition1) Prior Guidance Updated Guidance 2026 Anticipated (In millions, except per share amounts) As of February 23, 2026 As of May 4, 2026 Quarterly Dynamics Total Revenues $3,325 to $3,425 $3,825 to $3,925 • More
Slide 10: Commercial Update
Commercial Update Cristin Hubbard Chief Commercial Officer 10
Slide 11: Enzyme Therapies: Durable Performance in Q1'26
Enzyme GROWTH Therapies Enzyme Therapies: Durable Performance in Q1’26 Enzyme Therapies Q1’26 Revenue Strong Patient Demand; Early Momentum $ in millions in PALYNZIQ Adolescent Launch +6% Y/Y • 6% Y/Y growth, led by VIMIZIM, NAGLAZYME, and BRINEURA • PALYNZIQ Key Dynamics: +12% • Continued expansion
Slide 12: Skeletal Conditions: Strong Underlying Demand in Q1'26
Skeletal Conditions Skeletal Conditions: Strong Underlying Demand in Q1’26 Revenue Q1’26 Dynamics $ in millions • Ongoing patient additions across all regions and strong adherence; ~75% Q1 VOXZOGO revenue OUS1 • More than 20% Y/Y increase in children treated with VOXZOGO +3% • Focus on early diagnos
Slide 13: Research & Development Update
Research & Development Update Greg Friberg Chief R&D Officer 13
Slide 14: VOXZOGO: Expanding Evidence to Support Long-term Benefit
VOXZOGO: Expanding Evidence to Support Long-term Benefit Data presented at the Pediatric Endocrine Society (PES) annual meeting showed sustained improvements across growth, proportionality, and quality-of-life related measures Arm Span Z-score (ACH-referenced) Height and Height Z-score (average stat
Slide 15: 2026 R&D Highlights
2026 R&D Highlights Candidate Condition Key Highlights ✓ Adolescents (12-17 y/o) U.S. Approval February Phenylketonuria • Adolescents (12-15 y/o) EU Approval Decision 2026 Enzyme Therapies • Phase 3 Topline Data Q2’26 BMN 401 ENPP1 deficiency • Phase 3 Full Data (Medical Congress) • Submissions for
Slide 16: IOMARIN
IOMARIN B <x 08 S) ee ee
Slide 17: Appendix
Appendix Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information
Slide 18: Reconciliation of GAAP Reported Net Income to Non-GAAP Income
Reconciliation of GAAP Reported Net Income to Non-GAAP Income(1) Please refer to slide 21 for footnotes to the table 18
Slide 19: Reconciliation of GAAP and Non-GAAP R&D and SG&A Expenses
Reconciliation of GAAP and Non-GAAP R&D and SG&A Expenses(1) Please refer to slide 21 for footnotes to the table 19
Slide 20: Reconciliation of GAAP Income from Operations to Non-GAAP Income from Operations
Reconciliation of GAAP Income from Operations to Non-GAAP Income from Operations(1) Please refer to slide 21 for footnotes to the table 20
Slide 21: Reconciliation of GAAP Diluted EPS to Non-GAAP Diluted EPS
Reconciliation of GAAP Diluted EPS to Non-GAAP Diluted EPS(1) (1) Certain amounts may not sum or recalculate due to rounding. (2) These amounts were included in SG&A and represent charges for severance in connection with the company’s plan to simplify its organizational design and strategic initiati
BioMarin Pharmaceutical — Q1 2026 Earnings Presentation on 6ix